# EDGAR Filing Document

**Accession Number:** 0001801834
**File Stem:** 0001178913-26-000080
**Filing Date:** 2026-1
**Character Count:** 3882
**Document Hash:** 715b62fe7824a419c8521c5c5b0b91d0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-000080.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001178913-26-000080

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260106

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAINREFORM LTD.
- **CENTRAL INDEX KEY:** 0001801834
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39481
- **FILM NUMBER:** 26511665

**BUSINESS ADDRESS:**
- **STREET 1:** 65 YIGAL ALON ST.
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6744316
- **BUSINESS PHONE:** 972-3-7177051

**MAIL ADDRESS:**
- **STREET 1:** 65 YIGAL ALON ST.
- **CITY:** TEL AVIV
- **STATE:** L3
- **ZIP:** 6744316

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### Form 6-K

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934
For the month of January 2026

Commission File Number: 001-39481

### PainReform LTD.
(Translation of registrant's name into English)

65 Yigal Alon St., Tel Aviv 6744316

Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ☐

This Form 6-K is incorporated by reference into the Company's Registration Statements on Form S-8 (Registration No. [333-257968](https://www.sec.gov/Archives/edgar/data/1801834/000117891321002298/0001178913-21-002298-index.htm) and [333-265902](https://www.sec.gov/Archives/edgar/data/1801834/000117891322002535/0001178913-22-002535-index.htm)) and the Company's Registration Statements on Form F-3 (Registration No. [333-282264](https://www.sec.gov/Archives/edgar/data/1801834/000117891324003107/0001178913-24-003107-index.htm), [333-254982](https://www.sec.gov/Archives/edgar/data/1801834/000117891321001257/0001178913-21-001257-index.htm), [333-276485](https://www.sec.gov/Archives/edgar/data/1801834/000117891324000139/0001178913-24-000139-index.htm), [333-277594](https://www.sec.gov/Archives/edgar/data/1801834/000117891324000788/0001178913-24-000788-index.htm), [333-283655](https://www.sec.gov/Archives/edgar/data/1801834/000117891324003929/0001178913-24-003929-index.htm) and [333-286941](https://www.sec.gov/Archives/edgar/data/1801834/000117891325001556/0001178913-25-001556-index.htm)), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

------

On January 6, 2026, the Adjourned Annual General Meeting of Shareholders of PainReform Ltd. (the "Company") approved each of the six proposals brought before the Company's shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company's Notice and Proxy Statement with respect to the Company's Annual General Meeting of Shareholders, dated November 25, 2025, attached as Exhibit 99.1 to the Company's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on November 25, 2025.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **PAINREFORM LTD.** |
| Date: January 6, 2026 | */s/* Ehud Geller |
|  | Ehud Geller<br> Executive Chairman of the Board and Interim Chief Executive Officer |

---

------